8. Haefner HK. Report of the International Society for the Study of Vulvovaginal Disease terminology and classification of vulvodynia. J Low Genit Tract Dis. 2007;11(1):48-49.
9. Huffman JW. Dyspareunia of vulvo-vaginal origin: causes and management. Postgrad Med. 1983;73(2):287-296.
10. Krychman ML. Vaginal estrogens for treatment of dyspareunia. J Sex Med. 2010 Nov 22;8:666-674. [Epub ahead of print]
11. Kao A, Binik YM, Kapuscinski A, Khalifé S. Dyspareunia in postmenopausal women: a critical review. Pain Res Manag. 2008;13(3):243-254.
12. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol. 2009;113 (5):1124-1136.
13. Lüdicke F, Johannisson E, Helmerhorst FM, et al. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76(1):102-107.
14. Strauhal MJ, Frahm J, Morrison P, et al. Vulvar pain: a comprehensive review. J Womens Health Phys Ther. 2007;31(3):6-22.
15. Harlow BL, Stewart EG. A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc. 2003;58(2): 82-88.
16. Goetsch MF. Vulvar vestibulitis: prevalence and historic features in a general gynecologic practice population. Am J Obstetr Gynecol. 1991; 164(6 pt 1):1609-1616.
17. Danielsson I, Sjöberg I, Stenlund H, Wikman M. Prevalence and incidence of prolonged and severe dyspareunia in women: results from a population study. Scand J Public Health. 2003;31 (2):113-118.
18. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1): 87-94.
19. Barditch-Crovo P, Witter F, Hamzeh F, et al. Quantitation of vaginally administered nonoxynol-9 in premenopausal women. Contraception. 1997;55(4):261-263.
20. American College of Obstetricians and Gynecologists. Disorders of the Vulva. ACOG Patient Education Pamphlet AP088. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
21. Ferrero S, Abbamonte LH, Giordano M, et al. Uterine myomas, dyspareunia, and sexual function. Fertil Steril. 2006;86(5):1504-1510.
22. Walid MS, Heaton RL. Dyspareunia: a complex problem requiring a selective approach. Sex Health. 2009;6(3):250-253.
23. Sobghol SS, Alizadeli Charndabee SM. Rate and related factors of dyspareunia in reproductive age women: a cross-sectional study. Int J Impot Res. 2007;19(1):88-94.
24. Ferrero S, Ragni N, Remorgida V. Deep dyspareunia: causes, treatments, and results. Curr Opin Obstet Gynecol. 2008;20(4):394-399.
25. Kim IY, Sadeghi F, Slawin KM. Dyspareunia: an unusual presentation of leiomyoma of the bladder. Rev Urol. 2001;3(3):152-154.
26. Akbulut S, Cakabay B, Sezgin A, Ozmen C. A rare cause of severe dyspareunia: a case report and literature review. Arch Gynecol Obstet. 2009 Apr 26. [Epub ahead of print.]
27. Ferrero S, Esposito F, Abbamonte LH, et al. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. 2005;83(3): 573-579.
28. Fisher KA. Management of dyspareunia and associated levator ani muscle overactivity. Phys Ther. 2007;87(7):935-941.
29. Bø K, Sherburn M. Evaluation of female pelvic-floor muscle function and strength. Phys Ther. 2005;85(3):269-282.
30. Royal College of Obstetricians and Gynaecologists. Female Genital Mutilation and its Management. Green-top Guideline No 53 (May 2009). www.rcog.org.uk/files/rcog-corp/Green Top53FemaleGenitalMutilation.pdf. Accessed April 4, 2011.
31. Payne KA, Binik YM, Amsel R, Khalifé S. When sex hurts, anxiety and fear orient attention towards pain. Eur J Pain. 2005;9(4):427-436.
32. Pukall CF, Binik YM, Khalifé S, et al. Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. Pain. 2002;96(1-2):163-175.
33. Meana M, Binik YM, Khalifé S, Cohen D. Psychosocial correlates of pain attributions in women with dyspareunia. Psychosomatics. 1999:40(6): 497-502.
34. Pelvic Pain Assessment Form (2008). International Pelvic Pain Society. www.pelvicpain.org/pdf/History_and_Physical_Form/IPPS-H&PformR-MSW.pdf. Accessed April 11, 2011.
35. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30(2):191-197.
36. Basson R. Sexuality and sexual disorders in women. In: Clinical Updates in Women’s Health Care Monograph. Washington, DC: American College of Obstetricians and Gynecologists. 2003;2(2):1-94.
37. Oberg K, Sjögren Fugl-Meyer K. On Swedish women’s distressing sexual dysfunctions: some concomitant conditions and life satisfaction. J Sex Med. 2005;2(2):169-180.
38. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191-208.
39. Quirk FH, Heiman JR, Rosen RC, et al. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Womens Health Gend Based Med. 2002;11(3): 277-289.
40. Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002;28(4):317-330.
41. van Lankveld JJ, Granot M, Weijmar Schultz WC, et al. Women’s sexual pain disorders. J Sex Med. 2010;7(1 pt 2):615-631.
42. Hathaway JK, Pathak PK, Maney R. Is liquid-based Pap testing affected by water-based lubricant? Obstet Gynecol. 2006;107(1):66-70.